Alpine Immune Sciences raises $48M Series A to advance vIgD immunotherapies for cancer and autoimmune disease

Alpine Immune Sciences raised $48 million in a Series A to advance its vIgD-based immunotherapies for cancer and autoimmune diseases, backing programs that either stimulate anti-tumor immunity or suppress harmful autoimmune responses.

No comments yet.